Fujian Genohope Biotech Ltd

福建吉诺霍普生物科技有限公司成立于 2019 年，由新希望豪森卡兄弟和台湾吉诺维奥生物科技股份有限公司共同创立。公司位于福建省莆田市国家“海峡两岸生物技术与健康医疗产业合作区”。公司现有员工 220 人，2023 年，公司入选福建省专精特新企业。

该公司专注于高效多肽 API/溶液，并向全球市场销售多肽 API/溶液和制剂生产服务。公司总占地面积55亩，总建筑面积约70000平方米，建有研发中心约800平方米，质量控制中心1000平方米，GMP生产车间3300平方米。目前已建成11条生产线，其中重组肽原料药和全合成肽原料药制备生产线5条，注射液生产线6条。此外，公司还拥有大型抗肿瘤注射车间、小型多用途注射车间、大型多用途注射车间。生产线的建设和运营管理满足全球药品市场的监管要求，满足中美双注册申报。也可满足国内外客户的注册和销售。

产品优势：

目前，公司主要产品有索马鲁肽、Tirzepatide、美容药微球、胶原蛋白。特别是，公司具有成熟的 Semaglutide API 2 工艺制备优势，Semaglutide API 在美国 FDA 注册（DMF 编号：040957），Tirzepatide API 在美国 FDA 注册（DMF 编号：040503），

索马鲁肽 API 具有以下三个特点：价格低、质量高、产能（吨位）大。Tirzepatide API 在多肽制药行业广受好评。

    Fujian Genohope Biotech Ltd., is founded by New Hope Group, a Fortune Global 500 company, together with Genovior, fomous Taiwan peptide company and now a member of the Polaris Pharma Group, as the  globalized center for R&D and production of peptide products, located in the National Biotech and Health Industry Zone of Across-Strait in Putian City, Fujian Province. 
   The company focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with  a capacity of tons.

    In 2023, Genehope has been rewarded as Specialized and Novel Enterprise of Fujian Province.
In 2023 June, the US FDA completed its first on-site inspection for Genohope.